SPLIT-HAND/FOOT MALFORMATION 3
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
FBXO8, a gene of unknown function, is a member of the F-box gene family, among which FBXW4, within the minimal duplicated region associated with human split-hand/foot malformation type 3 (SHFM type 3).
|
24038848 |
2013 |
SPLIT-HAND/FOOT MALFORMATION 3
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Somatic/gonadal mosaicism in a syndromic form of ectrodactyly, including eye abnormalities, documented through array-based comparative genomic hybridization.
|
21485001 |
2011 |
SPLIT-HAND/FOOT MALFORMATION 3
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
The mutation of DAC gene can be excluded from cause of SHFM3 phenotype.
|
18067070 |
2007 |
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Leukemia, Myelocytic, Acute
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).
|
31661339 |
2020 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
The clinical activity of decitabine (5-aza-2-deoxycytidine, DAC), a hypomethylating agent, has been demonstrated in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients.
|
30793488 |
2019 |
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In the tumor cell-xenograft mouse model and ELISPOT assays, DAC increased the expression of MAGE-A3 and T cell mediated tumor clearance in ESCC as well.
|
30797153 |
2019 |
Neoplasms
|
0.090 |
PosttranslationalModification
|
group |
BEFREE |
Together, these experiments provide preclinical evidence that the FDA-approved DNA methylation inhibitor DAC may be repurposed to treat patients with osteosarcoma based on its efficacy to decrease proliferation, to induce osteoblast differentiation, and to reduce metastasis to visceral organs.<b>Significance:</b> These findings describe the effects of DNA methyltransferase inhibition on ERα and its potential role as a tumor suppressor in osteosarcoma.<i>See related commentary by Roberts, p. 1034</i><i>See related article by El Ayachi and colleagues; Cancer Res 79(5);982-93</i>.
|
30593524 |
2019 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Decitabine (5-Aza-2'-deoxycytidine, DAC), an anti-leukemic drug, is effective in treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
|
30210693 |
2018 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
The hypomethylating agents azacitidine (Vidaza®, AZA) and decitabine (Dacogen®, DAC) have been approved for the treatment of AML patients, but their mechanisms of action are poorly understood.
|
28404876 |
2017 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Undergoing allo-HSCT significantly improved the LFS and OS for the entire group of patients with AML in CR1, along with the DAC induction subgroup and for the group with unfavorable cytogenetics aged 41-60.
|
26149802 |
2015 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
DAC (5-aza-2-deoxycytidine) is an antitumor drug useful to lung cancer, myelodysplastic disorders, myelodysplasia and acute myeloid leukemia.
|
25611377 |
2015 |
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
DAC can restore expression of NALP1 to suppress tumor growth in colon cancer.
|
25611377 |
2015 |
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
The high expression levels of MAGE-A1, MAGE-A3, and NY-ESO-1 were sustained in sarcoma lines and primary tumor lines over 30 days after the cessation of DAC.
|
24584817 |
2014 |
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Cytotoxic T cells specifically recognizing MAGE-A family and NY-ESO-1 clustered at the tumor site in mice pre-treated with DAC and resulted in tumor growth suppression, while it was not observed in mice without DAC pre-treatment.
|
25301731 |
2014 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Preclinical data indicate that DAC is much more effective against human AML than ARA-C.
|
23660386 |
2013 |
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The p-GSK3β (Ser9) protein level in Caki-2 cells was significantly down-regulated, while the DNA fragmentation rate increased after treatment with 5 μM DAC at 96 h. Our data show that sFRP2 functions as a tumor suppressor gene in RCC and that its restoration may offer a new therapeutic approach for the treatment of RCC.
|
23975733 |
2013 |
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Taken together, we suggest that FBXW4 may be a novel tumor suppressor that regulates important cellular processes.
|
23658844 |
2013 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
This study, the first to investigate the relationship between TERT methylation and telomerase activity in leukemia cells, demonstrated a differential methylation pattern and response to DAC in three AML cell lines.
|
22517724 |
2012 |
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Putative methylation markers were selected from DAC-upregulated genes through a literature search and an upfront methylation-specific PCR on 20 primary neuroblastoma tumors, as well as through MBD- seq in combination with publicly available neuroblastoma tumor gene expression data.
|
23034519 |
2012 |
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Ovarian cancer cells (Hey and SKOv3) were treated with demethylating agents (5-aza-20-deoxycytidine [DAC] or 5-azacitidine [AZA]) or with HDAC inhibitors (suberoylanilide hydroxamicacid [SAHA] or trichostatin A [TSA]) to determine their impact on cellular proliferation, cell cycle regulation, apoptosis, autophagy, and re-expression of 2 growth inhibitory imprinted tumor suppressor genes: guanosine triphosphate-binding Di-RAS-like 3 (ARHI) and paternally expressed 3 (PEG3).
|
21491416 |
2011 |
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
The promoter of p73 was hypermethylated in AML cell lines in vitro and in primary AML cells ex vivo but not in DAC-resistant epithelial cells.
|
16193303 |
2005 |
MYELODYSPLASTIC SYNDROME
|
0.060 |
Biomarker
|
group |
BEFREE |
The clinical activity of decitabine (5-aza-2-deoxycytidine, DAC), a hypomethylating agent, has been demonstrated in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients.
|
30793488 |
2019 |
MYELODYSPLASTIC SYNDROME
|
0.060 |
Biomarker
|
group |
BEFREE |
Decitabine (5-Aza-2'-deoxycytidine, DAC), an anti-leukemic drug, is effective in treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
|
30210693 |
2018 |
MYELODYSPLASTIC SYNDROME
|
0.060 |
Biomarker
|
group |
BEFREE |
DAC (5-aza-2-deoxycytidine) is an antitumor drug useful to lung cancer, myelodysplastic disorders, myelodysplasia and acute myeloid leukemia.
|
25611377 |
2015 |